• Corvus Pharmaceuticals posted a GAAP net loss of $17.96 million, or $0.19 a share, for Q2 2026, widening from $8 million, or $0.10.
• R&D expense more than doubled to $15.96 million, due to higher soquelitinib clinical trial costs and higher personnel-related costs.
• Cash, cash equivalents and marketable securities rose to $215.23 million at June 30, extending expected operating runway into Q2 2028.
• Enrollment stayed on track in the registrational Phase 3 relapsed/refractory PTCL trial and the SIERRA1 Phase 2 atopic dermatitis study.
• Richard A. Miller said Corvus expects to start soquelitinib studies in hidradenitis suppurativa and asthma later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9805396) on August 06, 2026, and is solely responsible for the information contained therein.